AOS1

PF3D7_1144500 (AOS1) encodes subunit 1 of the Plasmodium falciparum SUMO E1-activating enzyme, which together with SUMO-activating enzyme subunit 2 (SAE2) forms the heterodimeric E1 that initiates the parasite sumoylation cascade by activating PfSUMO for transfer to the E2-conjugating enzyme Ubc9; the reconstituted P. falciparum E1 (containing AOS1) and E2 modify RanGAP1 in vitro (PMID:23943616). A defining feature of this complex is species-specific divergence at the E1–E2 binding interface: P. falciparum E1 fails to interact with human E2 and vice versa, and structure-guided modeling and mutagenesis pinpointed divergent surface residues that dictate these organism-specific interactions and preclude cross-reactivity with the human machinery (PMID:23943616, PMID:26697886). At the pathway level, sumoylation activity peaks during mid intra-erythrocytic stages coincident with hemoglobin consumption and oxidative stress, linking the AOS1-containing E1 pathway to the parasite oxidative stress response (PMID:23943616), and a resistance mutation in the partner subunit SAE2 confers benzoxaborole resistance, implicating the E1 sumoylation complex in an antimalarial mechanism-of-action pathway (PMID:31992618). Beyond its role as an E1 subunit in this heterodimer, no AOS1-specific catalytic or regulatory detail distinct from the complex has been characterized in the available corpus.

1. 2013 High

   Established that AOS1, as subunit 1 of the P. falciparum SUMO E1, forms a functional activating complex that hands SUMO to the E2 Ubc9, and that this E1–E2 pairing is species-specific rather than interchangeable with human enzymes.

   Evidence In vitro sumoylation of RanGAP1 with recombinant P. falciparum E1 and E2, plus heterologous cross-species interaction assays and structural/binding analysis

   PMID:23943616

   Open questions at the time

   • Does not isolate AOS1's individual contribution to adenylation versus that of SAE2
   • No in vivo confirmation of the cascade in parasites
   • Full set of physiological SUMO substrates beyond RanGAP1 unknown
2. 2013 Medium

   Placed the AOS1-containing sumoylation pathway in a physiological context by showing its activity peaks at mid intra-erythrocytic stages alongside oxidative stress, implicating it in the stress response.

   Evidence Immunoblot staging of sumoylation across the intra-erythrocyte cycle and oxidative stress treatment experiments

   PMID:23943616

   Open questions at the time

   • AOS1 itself was not directly manipulated—readout is global sumoylation
   • Causal role of AOS1 in stress protection not tested
   • Downstream sumoylated targets during stress not identified
3. 2015 High

   Resolved the molecular basis of species specificity by using a human E1 UFD–E2 crystal structure to guide modeling and mutagenesis of the P. falciparum E1–E2 interface, identifying surface residues that define parasite-specific interactions and non-cross-reactivity.

   Evidence X-ray crystallography of the human E1 UFD–E2 complex, in silico modeling of the P. falciparum interface, site-directed mutagenesis, and in vitro interaction assays

   PMID:26697886

   Open questions at the time

   • No experimental crystal structure of the P. falciparum E1 (AOS1) itself
   • Which residues reside on AOS1 versus SAE2 not fully partitioned
   • Interface residues not yet validated as druggable in cellular assays
4. 2020 Medium

   Connected the E1 sumoylation complex to antimalarial pharmacology by showing that a mutation in the partner subunit SAE2 confers high-level benzoxaborole resistance.

   Evidence In vitro resistance selection, whole-genome sequencing, engineered introduction of the SAE2 mutation, and IC50 determination

   PMID:31992618

   Open questions at the time

   • Resistance mutation is in SAE2, not AOS1—AOS1's own role in drug action untested
   • Mechanism by which the mutation confers resistance not defined
   • Whether the compound directly targets the E1 complex not established

• It remains unknown what distinguishes AOS1's catalytic and regulatory contribution from the E1 heterodimer as a whole, and whether AOS1 is genetically essential or directly druggable in the parasite.
• No AOS1-specific loss-of-function or essentiality data
• No standalone structure of AOS1
• Full SUMO substrate repertoire unresolved